Risperdal profits trump the $2 billion in criminal penalties
Posted on Tuesday, October 6th, 2015 at 2:38 pm
Johnson & Johnson’s aggressive marketing of the antipsychotic medication Risperdal has caused quite a controversy, especially since they allegedly withheld data about potential side effects such as breast development and stroke.
Upon its initial release in 1994, Johnson & Johnson had a small market for Risperdal, as the Food and Drug Administration said it was not necessarily better than any previous version of antipsychotics, and was targeted specifically for those suffering from schizophrenia . J&J later overhauled Risperdal and branded it as a medicine for a wide range of medical problems. Johnson & Johnson formed ElderCare and prescribed Risperdal even when it was not approved for consumption by the elderly. FDA protested and has reported numerous deaths among the ones who took the drugs.
Johnson & Johnson has profited handsomely from these crimes. Although they were hit with $2 billion in penalties and settlements, J&J has seen $30 billion in Risperdal sales around the world. If you know someone who has been harmed by the side effects brought by Risperdal, you may want to seek legal assistance in order to recover financial compensation. Speak with our experienced legal team at Williams Kherkher by calling us today at (888) 220-0640.